Provided by Tiger Fintech (Singapore) Pte. Ltd.

Beam Therapeutics, Inc.

26.44
+1.345.34%
Post-market: 27.000.5600+2.12%19:59 EST
Volume:2.29M
Turnover:59.07M
Market Cap:2.14B
PE:-5.77
High:27.43
Open:24.15
Low:23.63
Close:25.10
Loading ...

Cathie Wood's Bold Move: 8 Straight Days Of Buying Beam Therapeutics As Stock Soars 14%

Benzinga
·
2 hours ago

Beam Therapeutics Inc : Scotiabank Raises Target Price to $25 From $24

THOMSON REUTERS
·
03 Mar

Cautious Optimism for Beam Therapeutics Amid Upcoming Milestones and Financial Considerations

TIPRANKS
·
28 Feb

Beam Therapeutics Is Maintained at Sector Perform by RBC Capital

Dow Jones
·
27 Feb

Beam Therapeutics' Q4 Earnings & Revenues Beat Estimates

Zacks
·
26 Feb

Beam Therapeutics: Anticipated Growth Driven by BEAM-302 and SCD Franchise Progress

TIPRANKS
·
26 Feb

RBC Raises Price Target on Beam Therapeutics to $26 From $24, Keeps Sector Perform, Speculative Risk

MT Newswires Live
·
26 Feb

Bank of America Securities Keeps Their Hold Rating on Beam Therapeutics (BEAM)

TIPRANKS
·
26 Feb

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Addus Homecare (ADUS) and Beam Therapeutics (BEAM)

TIPRANKS
·
26 Feb

Beam Therapeutics (BEAM) Gets a Hold from Barclays

TIPRANKS
·
26 Feb

Beam Therapeutics Inc : Jefferies Raises Target Price to $30 From $23

THOMSON REUTERS
·
26 Feb

Beam Therapeutics Reports 2024 Financial Results and Progress

TIPRANKS
·
26 Feb

Beam Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
25 Feb

Beam Therapeutics Inc. (BEAM) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
25 Feb

Beam Therapeutics Swings to Q4 Loss as Revenue Falls

MT Newswires Live
·
25 Feb

Earnings Flash (BEAM) Beam Therapeutics Posts Q4 License and Collaboration Revenue $30.1M, vs. FactSet Est of $17.2M

MT Newswires Live
·
25 Feb